Lung Cancer
Volume 67, Issue 2 , Pages 248-250 , February 2010

Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event

  • Shotaro Ide

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
    • ,
  • Hiroshi Soda

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 956 24 1515; fax: +81 956 22 4641.
    • ,
  • Tomoaki Hakariya

      Affiliations

    • Division of Urology, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
    • ,
  • Shinnosuke Takemoto

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
    • ,
  • Hiroshi Ishimoto

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
    • ,
  • Shinya Tomari

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
    • ,
  • Toyomitsu Sawai

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
    • ,
  • Seiji Nagashima

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
    • ,
  • Masataka Furukawa

      Affiliations

    • Division of Urology, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
    • ,
  • Yoichi Nakamura

      Affiliations

    • Department of Second Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan
    • ,
  • Shigeru Kohno

      Affiliations

    • Department of Second Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan

Received 6 February 2009 ,Revised 24 August 2009 ,Accepted 8 October 2009.

References 

  1. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist. 2007;12:191–200
  2. Hanna NH, von Pawel J, Reck M, Scagliotti G. Carboplatin/paclitaxel with/without sorafenib in chemonaive patients with stage IIIB-IV non-small cell lung cancer: interim analysis results from a randomized phase III trial (ESCAPE) (abstract of the Chicago Multidisciplinary Symposium in Thoracic Oncology). J Thorac Oncol. 2008;3:S268
  3. Bayer HealthCare Japan. Safety information for Nexabar™ 200mg tablets. December 2008 (in Japanese).
  4. Rossi SE, Erasmus JJ, Volpacchio M, Franquet T, Castiglioni T, McAdams HP. “Crazy-paving” pattern at thin-section CT of the lungs: radiologic–pathologic overview. Radiographics. 2003;23:1509–1519
  5. Westocott JL, Cole SR. Traction bronchiectasis in end-stage pulmonary fibrosis. Radiology. 1986;161:665–669
  6. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165:378–381
  7. Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin. 2006;22:561–573
  8. Azuma A, Kudoh S. High prevalence of drug-induced pneumonia in Japan. Jpn Med Assoc J. 2007;50:405–411
  9. Ito S, Sumida T. Interstitial lung disease associated with leflunomide. Internal Med. 2004;43:1103–1104
  10. Ju JH, Kim SI, Lee JH, Lee SI, Yoo WH, Choe JY, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:2094–2096
  11. Camus P. Drug induced infiltrative lung disease. In:  Schwarz MI,  King TE editor. Interstitial lung disease.. Hamilton: BC Decker Inc; 2003;p. 485–534
  12. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case–control study. Am J Respir Crit Care Med. 2008;177:1348–1357
  13. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol. 2007;37:755–762

PII: S0169-5002(09)00535-2

doi: 10.1016/j.lungcan.2009.10.007

Lung Cancer
Volume 67, Issue 2 , Pages 248-250 , February 2010

Article Tools

* Image Usage & Resolution